Saltvae Pharmaceuticals Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 31-07-2024
- Paid Up Capital ₹ 5.00 M
as on 31-07-2024
- Company Age 3 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.50 M
as on 31-07-2024
- Revenue 1019.84%
(FY 2023)
- Profit 91.37%
(FY 2023)
- Ebitda 266.21%
(FY 2023)
- Net Worth -1.55%
(FY 2023)
- Total Assets 327.43%
(FY 2023)
About Saltvae Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹7.50 M.
Harnand Tyagi, Chander Goswami, and Rashi Goswami serve as directors at the Company.
- CIN/LLPIN
U24239UP2021PTC143662
- Company No.
143662
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Mar 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Noida, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Saltvae Pharmaceuticals Private Limited offer?
Saltvae Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Nutritional Supplements, Cardiovascular Drugs & Medication, Diabetes Medicine, Vitamin Tablets & Capsules, Ayurvedic,Herbal Products & Medicine, Ayurvedic Medicine, Mineral Supplement, Common Disease Medicines, Pharmaceutical Medicine.
Who are the key members and board of directors at Saltvae Pharmaceuticals?
Board Members(3)
Financial Performance and Corporate Structure Insights of Saltvae Pharmaceuticals.
Saltvae Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1019.84% increase. The company also saw a substantial improvement in profitability, with a 91.37% increase in profit. The company's net worth dipped by a decrease of 1.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Saltvae Pharmaceuticals?
In 2023, Saltvae Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
New Castle Finance And Leasing Private Limited
Active
34 years 2 months Harnand Tyagi is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 Jul 2023 | ₹4.50 M | Open |
Canara Bank Creation Date: 29 Jul 2022 | ₹3.00 M | Open |
How Many Employees Work at Saltvae Pharmaceuticals?
Unlock and access historical data on people associated with Saltvae Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Saltvae Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Saltvae Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
